Oncosem to Increase Capital 13‑fold Through a Free Capital Increase

Oncosem has approved a 1,200% free capital increase from internal sources, aiming to substantially expand its existing capital base. The move is viewed as a strategic step in the company’s capital structure. Under the decision, the capital of 23,850,000 TL will rise to 310,050,000 TL upon completion, representing roughly a 13‑fold increase. This growth will strengthen the company’s equity and positively impact its balance‑sheet health. A free capital increase reduces the debt ratio, thereby lowering financial risk. Expanding the equity base also provides a more solid foundation for future investment and growth projects. For investors, the development may temporarily reduce earnings per share (EPS) per share, but the bolstered capital base can enhance the company’s competitive strength over the long term. Short‑term price effects will depend on market expectations. The company’s strategic move aligns with capital‑increase trends in its sector and supports its goal of sustaining financial performance. This is not investment advice.